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Abstract
The goal of the present study was to evaluate the effects of SGLT2i on cardiac contractile function, 
substrate utilization, and efficiency before and during regional myocardial ischemia/reperfusion 
injury in normal, metabolically healthy swine. Lean swine received placebo or canagliflozin (300 
mg PO) 24 h prior to and the morning of an invasive physiologic study protocol. Hemodynamic 
and cardiac function measurements were obtained at baseline, during a 30-min complete occlusion 
of the circumflex coronary artery, and during a 2-h reperfusion period. Blood pressure, heart rate, 
coronary flow, and myocardial oxygen consumption were unaffected by canagliflozin treatment. 
Ventricular volumes remained unchanged in controls throughout the protocol. At the onset of 
ischemia, canagliflozin produced acute large increases in left ventricular end-diastolic and systolic 
volumes which returned to baseline with reperfusion. Canagliflozin-mediated increases in end-
diastolic volume were directly associated with increases in stroke volume and stroke work relative 
to controls during ischemia. Canagliflozin also increased cardiac work efficiency during ischemia 
relative to control swine. No differences in myocardial uptake of glucose, lactate, free fatty acids 
or ketones, were noted between treatment groups at any time. In separate experiments using a 
longer 60 min coronary occlusion followed by 2 h of reperfusion, canagliflozin increased end-
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diastolic volume and stroke volume and significantly diminished myocardial infarct size relative to 
control swine. These data demonstrate that SGLT2i with canagliflozin preserves cardiac 
contractile function and efficiency during regional myocardial ischemia and provides ischemia 
protection independent of alterations in myocardial substrate utilization.
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Introduction
The type 2 sodium–glucose cotransporter (SGLT2) is located in the S1 and S2 segments of 
the renal proximal tubules and is responsible for ~ 90% of glucose reabsorption in the 
kidney. In chronic hyperglycemia, SGLT2 activity is increased as a result of upregulation, 
exacerbating increases in plasma glucose concentration [31]. Inhibitors of this cotransporter 
(SGLT2i) reduce glucose reabsorption in the kidneys, resulting in increased urinary glucose 
excretion and a reduction in plasma glucose levels [22]. Cardiovascular outcome studies 
have demonstrated that SGLT2i also significantly reduces major adverse cardiovascular 
events in subjects with type 2 diabetes mellitus (T2DM) [3, 35, 46]. These cardiovascular 
benefits do not appear to be mediated by direct effects of these agents on the SGLT2 
transporter in cardiovascular tissues, as SGLT2 protein expression is not detected in the heart 
or vasculature [7, 20, 21]. These benefits are also not explained by improved glycemic 
control, as antidiabetes agents in other classes have provided similar improvements in 
glucose without parallel beneficial cardiac effects [30, 35, 46]. Furthermore, SGLT2i have 
been shown to improve cardiac function and mitigate myocardial infarct size in 
metabolically normal animal models [28, 39]. Improved arterial stiffness [8] and reduced 
blood pressure [9] have been reported with chronic SGLT2i treatment; however, it is unclear 
whether these effects are sufficient to explain the observed cardiovascular benefits.
In this context, the ‘thrifty fuel’ hypothesis has been proposed to explain the cardiovascular 
benefits of SLGT2i [33]. In particular, inhibition of SGLT2 has been demonstrated to 
augment circulating ketone bodies via alterations in hepatic fuel metabolism [15, 34]. Since 
ketone transport via the monocarboxyl transporter depends simply on the transmembrane 
gradient, increased ketone availability could serve to shift myocardial fuel utilization away 
from free fatty acids toward ketones, which require less oxygen per mole of ATP produced 
[5]. Some support for the plausibility of this ketone hypothesis in improving cardiac function 
and efficiency in response to pathologic stimuli such as ischemia has been presented [14]. 
However, studies to directly assess the effects of SGLT2i on myocardial substrate utilization 
during ischemia are presently lacking.
The goal of the present study was to evaluate the effects of SGLT2i on cardiac contractile 
function, substrate utilization, and efficiency before and during regional myocardial 
ischemia/reperfusion injury in normal, metabolically healthy swine. We tested the 
hypothesis that SGLT2i improves cardiac function and efficiency during ischemia/
reperfusion injury via shifts in myocardial substrate selection toward ketone utilization. To 
Baker et al. Page 2
Basic Res Cardiol. Author manuscript; available in PMC 2020 April 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
exclude contributions of effects of chronic exposure, we elected to perform studies following 
very short-term (24 h) exposure to SGLT2i. Invasive methodologies were used to obtain 
high-quality and precise in vivo measures of hemodynamics and cardiac function, including 
gold standard measurements of contractility. Findings from this study provide novel insight 
in to the acute, cardioprotective effects of SGLT2i during ischemic injury.
Methods
Animal model and surgical preparation
All experiments involving animals were approved by an Institutional Animal Care and Use 
Committee and performed in accordance with the Guide for the Care and Use of Laboratory 
Animals (National Institutes of Health Publication. No. 85–23, Revised 2011). Male 
domestic swine (~ 50 kg) were placed on a standard chow (5L80, Purina Test Diet, 
Richmond, IN, USA) and randomly assigned into Control or Treatment groups. Treatment 
animals were given canagliflozin (300 mg, oral) 24 h prior to and approximately 2 h before 
the acute/terminal procedure. Control animals received no treatment.
Left circumflex ischemia protocol
Following an overnight fast (~ 16 h), control (n = 7), and canagliflozin-treated (n = 8) swine 
were anesthetized with telazol (5 mg/kg), ketamine (3 mg/kg), and xylazine (2.2 mg/kg) 
cocktail (i.m.), and then, anesthesia was maintained with morphine (3 mg/kg) and α-
chloralose (100 mg/kg, i.v). Depth of anesthesia was monitored by observing continuous 
measurements of arterial blood pressure and heart rate as well as regular (15-min intervals) 
reflex tests (corneal, jaw, and limb withdrawal), beginning after induction of anesthesia and 
continuing throughout the experimental protocol. Periodic supplementation with α-
chloralose was performed every 1.5 h to maintain a level, stage 3 plane of anesthesia. The 
right femoral artery and vein were isolated and catheterized to allow measurement of 
systemic arterial pressure and maintain venous access, respectively. The heart was exposed 
by a left lateral thoracotomy. The proximal region of both the left anterior descending artery 
(LAD) and left circumflex artery (LCX) was isolated for placement of perivascular flow 
probes (Transonic Systems Inc., Ithaca, NY, USA) and a snare occluder was placed around 
the left circumflex artery. A catheter was then placed in the intraventricular vein to allow 
sampling of coronary venous blood from the area supplied by the LAD. A SciSense 
pressure/volume admittance catheter (Transonic Scisense, London Ontario, Canada) was 
passed through a hemostatic control valve placed directly into the left ventricle via a 
transmural stab near the base of the left ventricle and secured with a purse string suture. 
Measurements were obtained at baseline, during a 30 min complete occlusion of the LCX, 
and during a 2-h reperfusion. At the beginning of the study, a total of 20 animals were 
enrolled (10 per group; randomized). Three swine from the control group and two swine 
from the canagliflozin group fibrillated during the coronary occlusion portion of the protocol 
and were thus not included in the study.
Metabolic analysis
Arterial (5 mL) and coronary venous (5 mL) blood samples were collected simultaneously 
into untreated syringes, immediately sealed, and placed on ice. These samples were 
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collected every 15 min during baseline and the coronary occlusion, and every 30 min during 
reperfusion; total blood samples across the 2–3 h experimental protocol summed to < 100 
mL from an estimated ~ 4 to 5 L total circulating blood volume. The samples were analyzed 
immediately upon collection for pH, PCO2, PO2, O2 content, glucose, lactate, and 
hematocrit with an Instrumentation Laboratories automatic blood gas analyzer (GEM 
Premier 4000). Free fatty acids (NEFA—Non-Esterified Fatty Acids) were measured 
colorimetrically (WAKO Life Sciences, City State) and ketones were analyzed with a 
chemistry analyzer (Roche Hitachi Modular P, Indianapolis, IN, USA), reporting 
concentrations of β-hydroxybutyrate and acetone as total ketone measure. Myocardial 
oxygen consumption (MvO2;μL O2/min/g) was calculated using the Fick principle [coronary 
blood flow × (arterial O2 content−coronary venous O2 content)]. For these calculations, 
LAD perfusion territory was estimated to be 30% of total heart weight, as previously 
described [13]. The Fick principle was also used to calculate substrate uptake (glucose, 
lactate, free fatty acids, and ketone), [coronary blood flow × (arterial substrate content
−coronary venous substrate content)]. Accordingly, the term “uptake” refers to the result of 
the Fick calculation and it should be recognized that this variable does not account for the 
degree to which substrate production by the tissue (e.g., lactate) contributes to the reported 
value. Cardiac efficiency was calculated as cardiac work (product of cardiac output and 
mean arterial pressure) divided by MvO2.
Infarct protocol
Additional studies to assess the effects of SGLT2i on myocardial infarct size were also 
performed in control (n = 8) and canagliflozin-treated (n = 8) swine. Owing to the fact that 
historic attempts at proximal occlusions of the LCX have resulted in high mortality rates 
with prolonged ischemic duration as well as variable access to distal LCX territories, these 
studies were performed in the distal LAD region, as previously described [17, 18]. In these 
experiments, the distal LAD was subjected to a 60 min occlusion followed by 2 h of 
reperfusion. Durations of ischemia and reperfusion were selected based on literature support 
indicating that the stimulus would be adequate and appropriate for induction of regional 
myocardial infarction [17, 18]. Four swine fibrillated during the LAD coronary occlusion 
portion of this protocol (n = 2 in each group) and thus were not included in infarct analyses. 
Therefore, for infarct analyses, the final n = 6 for each group.
Hemodynamic data were collected in these animals as well. However, due to a failure of the 
pressure volume catheter, we were unable to reliably obtain pressure volume loops for two 
animals in the infarct study (n = 1 per group). As a result, the n for metrics associated with 
the pressure–volume catheter (left ventricular pressures, volumes, and derived measures) is 5 
per group.
Infarct quantification
At the completion of each experiment, hearts were fibrillated by direct application of a 9 V 
battery and excised. Hearts were then sliced into 1-cm-thick sections and incubated in 1% 
2,3,5-triphenyltetrazolium chloride (TTC) solution for 20 min at 37°C. Following incubation 
with TTC solution, a digital image of each heart slice was captured by a Canon Eos-Rebel 
sl1 with an associated 18–55 mm lens, capturing 18.0 MP images in RAW format. No 
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measurable infarct was detected in animals subjected to LCX occlusion regardless of 
treatment (control n = 3; SGLT2i n = 4) and those animals are, accordingly, not included in 
infarct analyses. Measurable infarct was present and consistent in animals who received the 
longer (60 min) occlusion of the distal LAD. In those animals, quantification of infarct area 
(unstained) vs. viable myocardium (stained) was performed using the ImageJ software 
(National Institutes of Health). Each heart slice was evaluated by three separate investigators 
who were blinded to experimental treatment group. Data are presented as averaged area for 
left ventricle (stained) and infarct area (unstained); the coefficient of variation between the 
three investigators was 7% for the total left ventricle area and 9% for the infarcted area.
RNA isolation and cDNA synthesis
Tissue mRNA was prepared using a miRNeasy Mini Kit (Qiagen Cat#1038703). Flash 
frozen (500 mg) pig heart (n = 5) and kidney (n = 5) samples from domestic swine were 
homogenized in 2 mL Qiazol with a Polytron homogenizer (Kinematica Model PT3100) at 
1000 rpm until clear homogenate was observed (1–2 min in cold room on ice bath). The 
homogenate was vigorously shaken for 15 s with 380 μL chloroform. Total RNA was 
isolated from the upper aqueous phase according to the kit protocol using on-column DNA 
digestion. cDNA was synthesized from 500 ng total RNA in a 20 μL reaction using a High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems Cat#4368814).
RT-PCR
The pig SGLT1 RT-PCR assay was obtained from ThermoFisher (Applied Bioscience 
catalog # Ss03374377_ m1). The SGLT2 assay was designed on the basis of whole genome 
shotgun sequence published in NCBI (Reference Sequence: NC_010445.4) and made by 
Integrated DNA Technologies, Inc. (Skokie, Illinois) as a custom assay. Primer/Probe 
sequences were: Pig SGLT2 Assay 1, reverse primer GAA TCC AGC TGA GCC ACT C, 
forward primer GGG AAG CGA TAC TGT CAG ATC, probe TGG AAA AGG ACC CCT 
CTG GAT TTG G.
The pig SGLT2 Assay 2, reverse primer GGA CAG GTA GAG GCG AAT G, forward 
primer CTC TTC GTG CCA GTG TAC C, probe CGC CGG TGTCAT TAC CAT GCC. 
cDNA was diluted 1:5 and RT-PCR was accomplished with Taqman 2X Universal PCR 
Master Mix (Applied Biosytems, catalog #4304437) in ABI Prism 7900HT Sequence 
Detection System (Applied Biosystems). Cycles for SGLT1 and 2 were normalized to 
housekeeping gene, peptidylpropyl isomerase A.
Statistical analyses
Data were analyzed using the SigmaPlot statistical package (version 11 Systat Software Inc, 
San Jose, CA, USA) and SPSS (version 22 IBM, Chicago, IL, USA). Data are presented as 
mean ± standard error. Comparisons were assessed by t test or two-way ANOVA; [factor A 
= treatment (time control/SGLT2i); factor B = condition (baseline/occlusion/reperfusion)] as 
appropriate. When significance was established with ANOVA, Student–Newman–Keuls 
post-hoc testing was performed to identify pairwise differences between treatment groups 
and conditions. Statistical significance was declared when P < 0.05.
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Results
mRNA expression of SGLT1 vs. SGLT2 in swine heart and kidney
Determination of the relative abundance of SLC5A1 transcript (the gene-encoding SGLT1 
protein) and SLC5A2 transcript (the gene encoding SGLT2 protein) was assessed by qPCR 
in kidney and left ventricular biopsies from domestic swine (n = 5). These analyses detected 
the presence of SGLT1 (Fig.1a) and SGLT2 (Fig.1b) mRNA in both heart and kidney. 
However, the abundance of both these transcripts was approximately 100-fold higher in 
kidney tissue than that of heart tissue.
Systemic effects of SGLT2i during ischemia/reperfusion injury of the LCX
Hemodynamic and blood gas data for control (n = 7) and canagliflozin (n = 8)-treated swine 
at rest and during LCX ischemia/reperfusion injury are provided in Table 1. The 24 h 
exposure to canagliflozin did not significantly affect baseline resting systolic arterial 
pressure (P = 0.16), diastolic arterial pressure (P = 0.93), or coronary blood flow (P = 0.56) 
(Table 1). Although canagliflozin-related decreases in arterial pH (P < 0.001) and hematocrit 
(P < 0.001) and increases in arterial PO2 (P < 0.001) were detected by ANOVA, values of 
these variables remained within physiologic limits throughout the experimental protocol 
(Table 1).
Mean arterial pressure decreased from ~ 85 ± 5 mmHg at baseline to ~ 70 ± 5 mmHg 
following 30 min ischemia/reperfusion injury in control-and canagliflozin-treated swine 
(Fig.2a; Condition: P = 0.03; treatment: P = 0.53). Heart rate averaged ~ 75 beats/min 
throughout the entire protocol in both untreated and treated swine (Fig.2b; Condition: P = 
0.98; treatment group: P = 0.80). None of the hemodynamic or blood gas parameters were 
significantly affected by 30 min ischemia/reperfusion (Table 1).
Effects of SGLT2i on cardiac contractile function during ischemia/reperfusion injury of the 
LCX
Under baseline conditions, canagliflozin had no effect on left ventricular end-diastolic 
volume (P = 0.69), end-systolic volume (P = 0.47), stroke volume (P = 0.76), or cardiac 
output (P = 0.92) (Fig.3). However, following the onset of regional myocardial ischemia 
(LCX occlusion), canagliflozin treatment was associated with a significant and acute 
increase in left ventricular end-diastolic volume (Fig.3a; P = 0.002) and left ventricular end-
systolic volume (Fig.3b; P = 0.03). These changes in cardiac volumes corresponded with a 
maintenance of stroke volume (Fig.3c; P = 0.03) and cardiac output (Fig.3d; P = 0.05) 
throughout the ischemic time period and were not observed in control animals. Canagliflozin 
did not affect load-dependent measures of cardiac function, including ejection fraction (P = 
0.14), dP/dtmax (P = 0.06), dP/dtmin (P = 0.30), or τ1/2 (P = 0.31) (Table 1). MvO2 of the 
non-occluded anterior coronary vascular bed was unaffected by canagliflozin or by 30 min 
ischemia/reperfusion in either group (Table 1).
Schematic representations of average steady-state left ventricular pressure–volume loops 
illustrating the effect of regional myocardial ischemia in control vs. canagliflozin-treated 
swine are provided in Fig.4. In control swine, these pressure–volume relationships 
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demonstrate an expected modest reduction of left ventricular end-diastolic volume and 
systolic pressure generation during regional ischemia (Fig. 4a). This was notably different in 
the canagliflozin-treated animals, which showed a substantial right shift of the pressure–
volume relationship (Fig. 4b). Comparisons of the relationship between stroke volume vs. 
end-diastolic volume and cardiac output vs. end-diastolic volume (Frank–Starling 
relationship) during ischemia in control and canagliflozin-treated swine are provided in Fig.
4. These plots reveal that canagliflozin-mediated increases in stroke volume (Fig. 4c) and 
cardiac output (Fig. 4d) were directly related to increases in end-diastolic volume (preload). 
Left ventricular end-diastolic pressure was unaffected by 30 min ischemia/reperfusion or 
SGLT2i with canagliflozin (Table 1).
Stroke work [stroke volume (mL) × mean arterial pressure (mmHg)] and efficiency [cardiac 
output (mL/min) × mean arterial pressure (mmHg)]/MvO2 (μL O2/min/g) were unaffected 
by canagliflozin treatment under baseline conditions (Fig. 5). However, stroke work (Fig.5a; 
P < 0.001) and efficiency (Fig. 5b; P = 0.03) were significantly increased by canagliflozin 
administration during regional myocardial ischemia compared to control swine.
Effects of SGLT2i on myocardial substrate selection during ischemia/reperfusion injury of 
the LCX
Administration of canagliflozin augmented arterial free fatty acid concentration (Table 2; P 
= 0.017). However, circulating concentrations of other cardiac substrates including glucose 
(P = 0.087), lactate (P = 0.336) and total ketone bodies (acetoacetone and 3-
hydroxybutyrate) (P = 0.74) were unaffected by SGLT2i (Table 2). Canagliflozin did not 
significantly influence uptake of glucose (P = 0.75), lactate (P = 0.26), ketones (P = 0.41), or 
free fatty acids (P = 0.31) (Fig. 6), under resting conditions, during the 30 min ischemia, or 
during reperfusion.
Effect of SGLT2i on myocardial infarct size and cardiac function in response to 60 min LAD 
occlusion
No evidence of myocardial infarction was detected in either control (n = 3) or SGLT2i (n = 
4)-treated hearts following the 30 min LCX occlusion protocol. Therefore, to better assess 
potential effects on magnitude of myocardial infarction, a 60 min occlusion with 2 h 
reperfusion was performed in a separate cohort of animals in the distal LAD region. The 
rationale for a change in perfusion territory was based on historic attempts at longer term 
proximal occlusions of the LCX which resulted in marked increases in mortality [17, 18]. 
Therefore, our additional cohort of animals was modeled after established protocols 
demonstrating reliable induction of myocardial infarction with higher survival rates 
following 60 min occlusion of the distal LAD in swine [17, 18].
In contrast to data from the 30 min LCX occlusion, TTC staining of hearts from the 60 min 
LAD occlusion protocol revealed that treatment with canagliflozin (n = 6) significantly 
reduced infarct size by ~ 60% compared to control (n = 6) swine (Fig. 7; P = 0.03). In 
addition, canagliflozin treatment produced similar effects following the onset (15 and 30 
min) of the distal LAD occlusion, including a significant increase in left ventricular end-
diastolic volume and stroke volume (Supplemental Figure; P = 0.01) compared to control 
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swine. Heart rate was significantly lower in the SGLT2i group at the later ischemic 
timepoints (≥ 30 min occlusion) (Supplemental Table). However, this reduction was not 
associated with alterations in end-diastolic volume or stroke volume at either 45 or 60 min 
occlusion.
Discussion
There is a growing body of evidence supporting beneficial cardiovascular effects of SGLT2i 
in the setting of obesity/type 2 diabetes [3, 35, 46] and in normal, metabolically healthy 
animal models [28, 39]. However, there was no a priori reason to expect such beneficial 
effects of these glucosuric agents, and the mechanisms underpinning these unexpected 
effects are unknown. As such, whether effects of SGLT2i are the result of direct action on 
cardiomyocytes or other cardiac cells, or are secondary to extra-cardiac effects of SGLT2i 
remains undetermined. A proposed mechanism to explain SGLT2i-associated improvements 
in major adverse cardiovascular events as well as reductions in myocardial infarct size [3, 
[28] centers around the “thrifty fuel hypothesis” [5, 16, 34, 42]. This hypothesis is based on 
a recognized effect of SGLT2i to induce ketone production, which by providing ketones to 
the heart may improve cardiac efficiency by shifting myocardial substrate utilization away 
from free fatty acids [5, 14]. Accordingly, we set out to evaluate the effects of the SGLT2i 
canagliflozin on cardiac contractile function, substrate utilization, and efficiency before and 
during regional myocardial ischemia/reperfusion injury in normal, metabolically healthy 
swine. We observed effects of canagliflozin to augment cardiac function during regional 
myocardial ischemia and reduce myocardial infarct size, but these effects were independent 
of alterations myocardial substrate utilization. These observations argue against 
contributions of ketone-induced shifts in fuel selection to the cardioprotective effects of 
SGLT2i.
Cardiac effects of SGLT2i
Here, we show for the first time that SGLT2i produces a prominent and sustained increase in 
left ventricular volumes during regional myocardial ischemia in otherwise normal, 
metabolically healthy swine. There was no evidence of these effects under baseline 
conditions, and they abated during reperfusion (Fig. 4). Furthermore, these effects were not 
associated with any changes in arterial blood pressure (afterload) or heart rate (ventricular 
filling time) (Fig. 2). These data are consistent with recent rodent investigations which 
demonstrate that SGLT2i was able to preserve cardiac function in pressure-overload-induced 
heart failure mice independent of changes in afterload, as cardioprotection was evident both 
in vivo and in subsequent isolated heart studies [6].
Significant increases in end-diastolic volume could be interpreted as potentially deleterious, 
as volume overload is commonly associated with dilated cardiomyopathy and/or 
exacerbation of myocardial infarction. In this study, however, changes in ventricular volume 
handling were seen only during ischemia and reversed with relief of ischemia, at least under 
these acute exposure conditions. The timeline of the ischemia in this study (minutes) would 
not allow for the necessary remodeling associated with a dilated cardiomyopathy phenotype. 
Furthermore, interpretation of this study is simplified, as effects were evident in the absence 
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of measurable myocardial infarction, as measured by TTC staining in the 30 min LCX 
occlusion study. The lack of myocardial infarction following a 30 min coronary occlusion is 
consistent with previously published studies in swine [17, 23, 24, 40]. Therefore, changes in 
ventricular volume handling must occur independent of ventricular remodeling and/or 
infarction. Our observations of unchanged end-diastolic pressure suggest that SGLT2i 
enhanced ventricular compliance; however, no significant differences in global indices of 
diastolic function (dP/dtmin, τ) were noted.
Although we did not observe any evidence of myocardial infarction following the 30 min 
LCX occlusion protocol, insights into potential infarct mitigating behavior of SGLT2i are 
fundamentally valuable. Therefore, we performed additional studies in a separate cohort of 
animals, wherein we subjected conditionally identical swine to a 60 min coronary artery 
occlusion. The LAD was occluded during these experiments, as longer duration LCX 
occlusion is associated with decreased survivability [17]. In these animals, we did observe 
significant SGLT2i-associated reduction in infarct size (Fig. 7). This finding is consistent 
with prior studies in rodent models which documented reductions in myocardial infarct size 
in response to ischemia/reperfusion injury [3, 28].
We were able to amplify small amounts of SGLT1 and SGLT2 mRNA from swine 
myocardial samples (Fig. 1), consistent with observations in human samples [7, 20, 21]. 
However, it is unclear whether the SGLT2i-mediated effects in this study are the result of 
direct and/or indirect actions on the heart. As initial dosing was 24 h prior to the acute study, 
the potential for paracrine/humoral mediation exists. The 300 mg oral dosing regimen 
utilized in this study was selected to directly parallel the “high-dose” utilized clinically. Prior 
studies indicate that a single oral dose of canagliflozin (300 mg) achieves a plasma Cmax of 
3480 ng/mL (7.67 μM) in humans with tmax of 1.5 h and a half-life of 14.9 h [11, 12, 41]. 
We estimate (using allometric scaling) that the maximal plasma concentration of 
canagliflozin in ~ 50 kg swine such as those used in the present study to be ~ 3757 ng/mL 
(assuming no plasma protein binding), which is comparable to exposure in humans [11, 12, 
41]. Given our present observations of clear effects of canagliflozin on myocardial function, 
it seems plausible that a myocardial receptor system might exist that is responsive to this 
agent but not from the SGLT2 protein family; e.g., sodium hydrogen exchanger-1 (NHE-1) 
discussed below. Therefore, further studies to determine dose dependence and direct vs. 
indirect actions of SGLT2i are needed.
Potential mechanisms underlying cardiac effects of SGLT2i
SGLT2i therapies have been demonstrated to augment circulating ketone bodies in type 2 
diabetes, thereby suggesting the “thrifty fuel hypothesis” of cardioprotection. We found that 
canagliflozin increased free fatty acid concentrations modestly, but did not affect arterial 
levels of lactate or ketone bodies (Table 2). Arterial glucose levels tended to be lower in the 
treatment group (P = 0.08); however, ischemia/reperfusion status had no effect on glucose 
levels on either group (P = 1.0). These data are consistent with prior studies of SGLT2i 
treatment in metabolically healthy humans who also exhibited no change in fasting plasma 
glucose or ketone concentrations [1]. Despite the modest changes in circulating substrate 
concentration that we observed, no changes in myocardial uptake of glucose, lactate, 
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ketones, or free fatty acid were seen (Fig. 6). Thus, while interventions such as insulin and 
malonyl CoA inhibition have been shown to improve contractile function during ischemia 
via promotion of the utilization of thirty fuels [16, 27, 43], this does not appear to be the 
explanation for the currently observed effects of SGLT2i. A caveat of the present study is 
that our findings were made in a metabolically normal animal model, under conditions of 
acute and controlled ischemia. Therefore, whether our findings extend to the setting of 
chronic treatment in patients with type 2 diabetes with or without acute ischemia merits 
future study.
It is well recognized that SGLT2i influence circulating blood volume, promoting osmotic 
diuresis, and natriuresis and reductions in plasma volume [8, 25]. Although we did not 
directly measure plasma volume, there was a modest, but significant decrease in hematocrit 
in SGLT2i treated swine which runs counter to anticipated effects of diuresis. Furthermore, 
the current observations are not consistent with beneficial effects of diuresis, as any 
reduction in plasma volume would be expected to reduce overall ventricular filling volumes, 
in contrast to our observed ~ 50% increase in end-diastolic volume during ischemia. In 
addition, no differences in hemodynamics or cardiac volumes were noted at baseline or 
during the reperfusion period (Fig. 3). Cardiovascular benefits associated with diuretic-
induced reductions in plasma volume are understood to result from preload lowering and 
associated decreased wall tension within the ventricle and direct reductions in Frank–
Starling-mediated cardiac force generation [10], again in contrast to what we observed. 
Together, these data argue against a role of diuresis in the observed effects of canagliflozin 
following short-term (single-day) therapy and acute ischemic insult.
An alternate hypothesis to potentially explain SGLT2i mediated cardioprotection is the 
“sodium hypothesis”. Recent evidence suggests that the SGLT2i-mediated effects could 
work via direct inhibition of NHE-1, as has been demonstrated in isolated cardiomyocytes 
from rats and rabbits [4, 44]. In conditions leading to cellular acidosis such as myocardial 
ischemia, NHE-1 has been shown to be activated resulting in a reversal of the Na+/Ca2+ 
exchanger and increase intracellular calcium [36, 37]. By extension, inhibition of NHE-1 
would act to lessen Ca2+ overload in cardiomyocytes during myocardial ischemia. 
Improvement in cytosolic Ca2+ handling also produces myriad effects on regulatory and 
contractile proteins within the cardiomyocyte [2, 19, 29, 38, 45]. As the interplay between 
developed tension and resting cardiomyocyte length can determine Starling effects [32], a 
mechanism that directly alters intracellular Ca2+ handling could potentially contribute to the 
effects seen in this investigation. Previous studies have demonstrated a reduction in infarct 
size in a swine model of ischemia/reperfusion with NHE-1 inhibitors [26]. These data are 
directionally consistent with our present observations, and suggest a direction for further 
systematic in vivo and in vitro studies to explore the potential mechanisms of SGLT2i-
mediated cardioprotection.
Conclusion
Data from these studies demonstrate that canagliflozin preserves cardiac contractile function 
and efficiency during acute regional myocardial ischemia through acute effects on cardiac 
volume regulation that cannot be explained by myocardial fuel switching. Furthermore, 
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SGLT2i reduces infarct size following 60 min ischemia. Findings from this study highlight 
the therapeutic potential for SGLT2i in metabolically normal subjects [39] and demonstrate 
the need for further investigations to both elucidate the mechanisms responsible for 
improvements in cardiac function during ischemia and to extend these studies into 
metabolically deranged cohorts as well as cohorts with normal glucose metabolism but 
abnormal cardiac function.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
qPCR for SGLT1 (a) and SGLT2 (b) in kidney (n = 5) vs. heart (n = 5) biopsies from 
domestic swine
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Fig. 2. 
Effects of ischemia/reperfusion injury on mean blood pressure (a) and heart rate (b) in 
control (n = 7) and SGLT2i (canagliflozin)-treated (n = 8) swine
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Fig. 3. 
Effect of ischemia/reperfusion injury on end-diastolic pressure (a), end-systolic volume (b), 
stroke volume(c) and cardiac output (d) in control (n = 7) and SGLT2i (canagliflozin)-
treated (n = 8) swine. *P <0.05 vs. control (same timepoint), †P <0.05 vs. baseline (same 
treatment)
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Fig. 4. 
Representative pressure–volume loops of average steady-state conditions at baseline and 
during regional myocardial ischemia in control (n = 7) (a) and SGLT2i (canagliflozin) (n = 
8)-treated (b) swine. Relationship between stroke volume (c) and cardiac output (d) and end-
diastolic volume during ischemia in control (n = 8) and SGLT2i (canagliflozin) (n = 7)-
treated swine
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Fig. 5. 
Effect of ischemia/reperfusion injury on cardiac stroke work (a), efficiency (b) in control (n 
= 7), and SGLT2i (canagliflozin)-treated (n = 8) swine. *P <0.05 vs. control (same 
timepoint)
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Fig. 6. 
Effect of ischemia/reperfusion injury on myocardial uptake of glucose (a), lactate (b), 
ketones (c), and free fatty acids (FFA) d in control (n = 7) and SGLT2i (canagliflozin)-
treated (n = 8) swine
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Fig. 7. 
Images in a show representative transmural sections of left ventricular slices from control (n 
= 6) and canagliflozin (n = 6)-treated swine. Quantification of total infarct area relative to 
total left ventricular area is presented in b. *P <0.05 vs. control
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